NeoStem (NBS) Stock Plummets Today on Disappointing Cardiac Stem-Cell Therapy Data

NEW YORK (TheStreet) -- Shares of NeoStem  (NBS) plummeted 25.52% to $5.05 in late morning trading Tuesday after the biotech company announced poor results from a trial of its proprietary cardiac stem-cell therapy NBS10.

NBS10, which used to be called AMR-001, missed two primary endpoints in the study to test the therapy's efficacy. The stem-cell therapy comes from a patient's own bone marrow and is injected into patients after a heart attack. The stem cells are then supposed to help blood flow and build cardiac muscle.

NeoStem's trial used non-invasive imaging to monitor blood flow through the heart six months after a one dose of NBS10 or a placebo. The study showed no difference between NBS and placebo, NeoStem said.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

The company announced the data at the American Heart Association annual meeting on Monday.

For more on this story, read TheStreet's Adam Feuerstein's in-depth coverage here.

NBS Chart NBS data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

More from Markets

Dow Jumps Nearly 300 Points as U.S. and China to Resume Trade Talks

Dow Jumps Nearly 300 Points as U.S. and China to Resume Trade Talks

S&P 500 Index Is Having One of Its Best Days This Year

S&P 500 Index Is Having One of Its Best Days This Year

Trump Trade War Is Raising Prices for U.S. Manufacturers, N.Y. Fed Survey Says

Trump Trade War Is Raising Prices for U.S. Manufacturers, N.Y. Fed Survey Says

Musk Thrusts Tesla Holders Into Legal, Financial Limbo as SEC Probe Goes Formal

Musk Thrusts Tesla Holders Into Legal, Financial Limbo as SEC Probe Goes Formal

Jim Cramer on JCPenney: No One Knows What They Are

Jim Cramer on JCPenney: No One Knows What They Are